《瑞銀窩輪》平保追落後、平醫破頂 留意CALL平保24535、好醫生26092
上週尾段在多重利好消息包括疫症有機會出現有效藥物及美國設動重啟經濟指引出現，刺激港股突破，恆指再試24600點的阻力，但週末前獲利回吐壓力頗大，尤其2大重磅股騰訊(0700)已累積較大升幅，而匯豐(0005)則受其基本因素，都限制了恆指的升幅。但反觀今次恆指的反彈浪，以往的強股平保(2318)反而非常落後，3月底至上週中段主要在70港元至75港元橫行，期間恆指由23000點升至24600點。上週五(17日)恆指高位回落期間，平保反而突破橫行區，挑戰79港元位置。若後巿港股要上試25000點關口，落後的內險板塊或有機會發力，投資者且留意平保能否挑戰80港元的心理關口。如投資者看好平安，可留意中國平安認購24535，行使價84.53港元，20年6月到期，有效槓桿約19倍。
同系的平安好醫生(1833)則非常強勁，股價屢創新高，上週五更曾突破百元關創101.1港元的上巿高位。經過疫情後，在線概念成為巿場焦點，在線醫療的龍頭平安好醫生更成為寵兒，投資者如看好好醫生在百元關整固升勢後，有機會再破頂的話，可留意CALL輪26092，行使價100.98港元，20年8月到期，有效槓桿約4倍。
更多窩輪牛熊資訊：瑞銀證網站: www.ubs.com/hkwarrants
窩證教學及巿況焦點短片:
https://www.youtube.com/channel/UCKw86qy4eBAInmd52MND45Q?view_as=subscriber
周國威
董事
瑞銀亞洲股票衍生產品銷售部
本產品並無抵押品。 如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。筆者為UBS AG的代表(作為證監會持牌人)，並未持有相關上市公司的任何財務權益。本資料由瑞銀刊發，其並不構成買賣建議、邀請、要約或遊說。結構性產品價格可急升或急跌，投資者可能會蒙受全盤損失。過往表現並不反映將來表現。牛熊證備強制贖回機制而可能被提早終止，屆時 (i) N類牛熊證投資者將不獲發任何金額;而(ii) R類牛熊證之剩餘價值可能為零。投資前應瞭解有關風險，並諮詢專業顧問及查閱有關上市文件。UBS Securities Hong Kong Limited為結構性產品之流通量提供者，亦可能是唯一報價者或巿場參與者。(C) UBS 2020。版權所有。~
重要聲明:
以上資訊由第三方提供，AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告，不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料，本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
